Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that Adasuve now will be launched for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disorder. Medivir entered a license and distribution agreement for the commercialization of Adasuve with Ferrer in September 2013. Adasuve is a brand new inhalable treatment of agitation and is approved by EMA (European Medicines Agency) for sale in Europe.
Help employers find you! Check out all the jobs and post your resume.
